United States


VVUS.OQ on NASDAQ Stock Exchange Global Select Market

14 Dec 2017
Change (% chg)

$-0.02 (-3.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)


Beta: 0.79
Market Cap(Mil.): $58.22
Shares Outstanding(Mil.): 105.86
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 32.07 15.47
EPS (TTM): -- -- --
ROI: -- 15.07 33.71
ROE: -- 16.57 16.38

BRIEF-Vivus reports third quarter 2017 financial results

* Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively​

Nov 07 2017

BRIEF-VIVUS and Alvogen announce marketing agreement for Qsymia in the Republic of Korea

* VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea​​

Sep 05 2017

BRIEF-Dr.Reddy's Labs says overall impact on financials of settlement disputes with Vivus not likely to be material

* Dr.Reddy's Laboratories clarifies on news item regarding settling patent row with vivus

Sep 01 2017

BRIEF-Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation

* Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation

Aug 30 2017

Vivus, Teva settle lawsuit over Teva's planned generic Qsymia

Vivus Inc has reached an agreement allowing Teva Pharmaceuticals Ltd to launch a generic version of its anti-obesity drug Qsymia by December 2024, settling a patent lawsuit Vivus brought in New Jersey federal court.

Jul 06 2017

BRIEF-Vivus announces settlement with Actavis on Qsymia patent litigation

* Vivus announces settlement with actavis on qsymia(r) patent litigation

Jul 05 2017

Earnings vs. Estimates